These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39311378)

  • 1. Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays.
    Vroemen WHM; Agata SS; van Beers JJBC; Damoiseaux JGMC
    Antibodies (Basel); 2024 Sep; 13(3):. PubMed ID: 39311378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations.
    van Bezooijen JS; Koch BC; van Doorn MB; Prens EP; van Gelder T; Schreurs MW
    Ther Drug Monit; 2016 Aug; 38(4):432-8. PubMed ID: 27120178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays.
    Afonso J; Lopes S; Gonçalves R; Caldeira P; Lago P; Tavares de Sousa H; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Coelho R; Tavares P; Soares J; Sousa AL; Carvalho D; Sousa P; da Silva JP; Meira T; Silva Ferreira F; Dias CC; Chowers Y; Ben-Horin S; Magro F;
    Therap Adv Gastroenterol; 2016 Nov; 9(6):781-794. PubMed ID: 27803733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation.
    Karsten C; Grannas K; Bergman O; Movérare R; Roforth M; Willrich MAV; Snyder MR; Yang YK
    AAPS J; 2024 Jul; 26(5):86. PubMed ID: 39044059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay.
    Vande Casteele N; Yang L; Dobler I; Agboton C; McRorie Osborn T; Suri A; Lindner D; Smithson GM
    Ther Drug Monit; 2023 Apr; 45(2):236-244. PubMed ID: 36788448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational Study.
    Berger AE; Duru G; de Vries A; Marini JC; Aoucheta D; Cornillie F; Nancey S; Detrez I; Gils A; Roblin X; Paul S
    Ther Drug Monit; 2019 Aug; 41(4):459-466. PubMed ID: 30817702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of anti-drug monoclonal antibody panels against adalimumab and infliximab.
    Suzuki T; Tada M; Ishii-Watabe A
    Biologicals; 2020 Jan; 63():39-47. PubMed ID: 31883741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients With Noninfectious Uveitis.
    Bellur S; McHarg M; Kongwattananon W; Vitale S; Sen HN; Kodati S
    JAMA Ophthalmol; 2023 Feb; 141(2):150-156. PubMed ID: 36547953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory.
    Keating PE; Hock BD; Chin PKL; O'Donnell JL; Barclay ML
    Ther Drug Monit; 2024 Oct; 46(5):619-626. PubMed ID: 38648648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence.
    Sun X; Cui Z; Wang Q; Liu L; Ding X; Wang J; Cai X; Li B; Li X
    Autoimmun Rev; 2024 Apr; 23(4):103530. PubMed ID: 38499168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10
    Berger AE; Gleizes A; Waeckel L; Roblin X; Krzysiek R; Hacein-Bey-Abina S; Soriano A; Paul S
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076966
    [No Abstract]   [Full Text] [Related]  

  • 12. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region.
    van Schie KA; Hart MH; de Groot ER; Kruithof S; Aarden LA; Wolbink GJ; Rispens T
    Ann Rheum Dis; 2015 Jan; 74(1):311-4. PubMed ID: 25342759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.
    Quistrebert J; Hässler S; Bachelet D; Mbogning C; Musters A; Tak PP; Wijbrandts CA; Herenius M; Bergstra SA; Akdemir G; Johannesson M; Combe B; Fautrel B; Chollet-Martin S; Gleizes A; Donnellan N; Deisenhammer F; Davidson J; Hincelin-Mery A; Dönnes P; Fogdell-Hahn A; De Vries N; Huizinga T; Abugessaisa I; Saevarsdottir S; Hacein-Bey-Abina S; Pallardy M; Broët P; Mariette X;
    Semin Arthritis Rheum; 2019 Jun; 48(6):967-975. PubMed ID: 30420245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays.
    Rocha C; Lago P; Fernandes S; Correia L; Portela F; Vieira AI; Patita M; Arroja B; Ministro P; Alves C; Dias CC; Magro F
    Therap Adv Gastroenterol; 2020; 13():1756284820965790. PubMed ID: 33281935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Two Clinical Laboratory Assays for Measuring Serum Adalimumab and Antibodies to Adalimumab.
    Jain D; Pido MTJ; Delgado JC; Willrich MAV; Lázár-Molnár E
    J Appl Lab Med; 2023 Nov; 8(6):1054-1064. PubMed ID: 37658801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels.
    Pérez I; Fernández L; Sánchez-Ramón S; Alba C; Zatarain A; Cañas M; López ON; Olivares D; Rey E; Taxonera C
    Therap Adv Gastroenterol; 2018; 11():1756284818783613. PubMed ID: 30034528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.
    Reinisch W; Jahnsen J; Schreiber S; Danese S; Panés J; Balsa A; Park W; Kim J; Lee JU; Yoo DH
    BioDrugs; 2017 Jun; 31(3):223-237. PubMed ID: 28497221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
    Freeman K; Connock M; Auguste P; Taylor-Phillips S; Mistry H; Shyangdan D; Court R; Arasaradnam R; Sutcliffe P; Clarke A
    Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.